Roya Mirzaei | Molecular Biology | Best Researcher Award

Posted on by Forensic Scientist

Dr. Roya Mirzaei | Molecular Biology | Best Researcher Award

Shahid Beheshti University of Medical of sciences | Iran

Dr. Roya Mirzaei is a distinguished Iranian toxicologist and biomedical researcher, currently serving as a Postdoctoral Research Fellow at the Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences (2023–2025). Her academic journey encompasses a Ph.D. in Toxicology (2017–2022) and an MSc in Toxicology (2013–2015) from the Islamic Azad University of Tehran Medical Sciences, following a Bachelor’s degree in Medical Laboratory Sciences from Hamedan University of Medical Sciences (2013). Dr. Mirzaei’s research is deeply rooted in cancer biology, immunotherapy, and molecular toxicology, with a particular focus on the development of recombinant antibodies and the exploration of natural toxins for therapeutic applications. Her prolific contributions to scientific literature and active participation in peer review processes underscore her commitment to advancing medical science.

Professional profile👤

Google Scholar

ORCID

Scopus

Strengths for the Awards✨

Dr. Roya Mirzaei demonstrates exceptional strength in interdisciplinary cancer research, toxicology, and immunopharmacology. With a Ph.D. in Toxicology and ongoing postdoctoral fellowship at the Shahid Beheshti University of Medical Sciences, her research trajectory reflects depth, innovation, and collaboration. Her scientific contributions include 16 peer-reviewed publications, many of which explore novel anti-cancer therapeutics using recombinant antibodies, mitochondrial targeting, and venom-derived compounds. Notably, her publication in high-impact journals like International Immunopharmacology (IF: 5.71) and Environmental Science and Pollution Research (IF: 5.8) marks her as a front-runner in translational research.

🎓 Education

  • Postdoctoral Research Fellow
    Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences (2023–2025)

  • Ph.D. in Toxicology
    Faculty of Pharmacy, Islamic Azad University of Tehran Medical Sciences (2017–2022)

  • MSc in Toxicology
    Faculty of Pharmacy, Islamic Azad University of Tehran Medical Sciences (2013–2015)

  • Bachelor’s Degree in Medical Laboratory Sciences
    Hamedan University of Medical Sciences (2013)

💼 Professional Experience

  • Scientific Researcher
    Recombinant Proteins Department, Motamed Cancer Institute (2021–2023)
    Dr. Mirzaei played a pivotal role in designing and implementing studies, collecting data, and analyzing results, particularly focusing on cancer stem cells and bi-specific antibodies.

  • Research Assistant
    Biotechnology Department, Pasteur Institute of Iran (2014–2018)
    She collaborated with students, provided research guidance, and executed various experimental techniques, contributing to projects involving venom-derived compounds and gene expression studies.

🔬 Research Interests On Molecular Biology

Dr. Mirzaei’s research interests are centered on the cellular and molecular mechanisms involved in cancer and its immunotherapy. She is particularly intrigued by the rapidly evolving fields of tumor immunology and cancer biology, employing both in vitro and in vivo models, as well as bioinformatics tools, to unravel complex biological processes. Her work often intersects with areas such as cellular immunology, cell biology, and the development of novel therapeutic strategies.

🏆 Awards & Honors

  • Top Researcher
    Student Section, Islamic Azad University of Medical Sciences, Tehran-Iran (2018 & 2023)

  • Editorial Board Member
    26th Edition of International Conference on Oncology and Cancer Research, Pencis (2025)

  • Memberships

    • Society of Toxicology (SOT), USA – Postdoctoral Member (2021–Present)

    • Iranian Society of Toxicology (IranTox) (2018–Present)

    • Iranian Society of Physiology and Pharmacology (PHYPHA) (2022–Present)

  • Educational Contributions

    • Co-authored the “IQB: Decennial Iran Question Bank” for Ph.D. Toxicology exams (2018)

    • Translated the latest edition of “Cecil Textbook of Medicine: Cardiovascular Diseases” into Persian (2021)

    • Conducted an online course on Clinical Toxicology via Faradars (2022)

📚 Publications

Dr. Mirzaei has an extensive list of publications in reputable journals. Below are selected works with hyperlinks, publication years, journals, and citation information:

  1. The Recombinant Anti-MET/EpCAM Bispecific Antibody Fragment: A Promising Novel Therapeutic Approach for Breast Cancer Treatment
    Investigational New Drugs, 2025.
    Link
    Cited by: 3 articles

  2. Exploring the Potential of Mitochondria-Targeted Drug Delivery for Enhanced Breast Cancer Therapy
    International Journal of Breast Cancer, 2025.
    Link
    Cited by: 2 articles

  3. Strain-Specific Effects of Probiotics on Depression and Anxiety: A Meta-Analysis
    Gut Pathogens, 2024.
    Link
    Cited by: 5 articles

  4. Production of Novel Recombinant Anti-EpCAM Antibody as Targeted Therapy for Breast Cancer
    International Immunopharmacology, 2023.
    Link
    Cited by: 6 articles

  5. Increased Risk of Primary Ovarian Insufficiency by High-Fructose Diet: A 90-Day Hormonal and Immunohistochemical Study in Wistar Rats
    Environmental Science and Pollution Research, 2022.
    Link
    Cited by: 3 articles

  6. The Role of High-Fructose Diet in Liver Function of Rodent Models: A Systematic Review of Molecular Analysis
    Iranian Biomedical Journal, 2023.
    Link
    Cited by: 2 articles

  7. Repurposing the Drug, Ivermectin, in COVID-19: Toxicological Points of View
    European Journal of Medical Research, 2022.
    Link
    Cited by: 4 articles

  8. Development of a MET-Targeted Single-Chain Antibody Fragment as an Anti-Oncogene Targeted Therapy for Breast Cancer
    Investigational New Drugs, 2023.
    Link
    Cited by: 5 articles

  9. Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity
    Iranian Journal of Immunology, 2023.
    Link
    Cited by: 2 articles

  10. Increased Risk of Cerebral Dysfunction by High-Fructose Diet Consumption: A 90-Day Study in Female Rats
    Health Biotechnology and Biopharma, 2023.
    Link
    Cited by: 1 article

🧾 Conclusion

Dr. Roya Mirzaei exemplifies the qualities of a dedicated and innovative researcher in the fields of toxicology and cancer biology. Her extensive academic background, coupled with her hands-on experience in leading research institutions, has led to significant contributions to scientific knowledge, particularly in the development of targeted therapies and the understanding of dietary impacts on health. Her commitment to education, as evidenced by her teaching and translation work, further highlights her dedication to the dissemination of scientific knowledge. Dr. Mirzaei’s achievements make her a deserving candidate for recognition and accolades in her field.

Esmaeil Babaei | Genetics | Best Researcher Award

Posted on by Forensic Scientist

Prof. Dr. Esmaeil Babaei | Genetics | Best Researcher Award

University of Tabriz | Iran

Dr. Esmaeil Babaei is a Professor of Molecular Genetics at the University of Tabriz, Iran, specializing in human cancer genetics and bioinformatics. With an H-index of 21 and 1,640+ citations, he has made significant contributions to cancer research, drug development, and biomarker discovery. He has led 15+ national/international projects, mentored 12 PhD and 45 MSc students, and developed 4 biotech products, including BRIzol (RNA extraction kit) and Curcuden35 (anticancer nanocurcumin).

Professional profile👤

Google Scholar

ORCID

Scopus

Strengths for the Awards✨

  1. High Research Productivity & Impact
    • 95 publications (JCR-indexed), H-index: 21, Citations: 1640 (Google Scholar).
    • Recent publications in high-impact journals (Microchemical Journal, Frontiers in Immunology, Phytomedicine).
    • International collaborations (Germany, Austria, Iraq) enhancing research visibility.
  2. Innovative & Translational Research
    • Developed four biotech products (e.g., BRIzol RNA extraction kit, Covid-19 PCR kit, Curcuden35 anticancer capsule, EBST bioinformatics tool).
    • Expertise in nanoformulations (curcumin-based therapies) and CRISPR/Cas9 applications in cancer.
  3. Leadership in Research & Mentorship
    • Principal Investigator (PI) of 15 research projects (11 national, 4 international).
    • Supervised 12 PhD, 45 MSc, and 2 postdoc alumni, demonstrating academic leadership.
  4. Recognition & Awards
    • Best International Researcher Award (2024, University of Tabriz).
    • Research grants from DFG (Germany), University of Salzburg (Austria).
    • Young Investigator Awards (INCTR Congress, Turkey).
  5. Multidisciplinary Expertise
    • Combines wet-lab (molecular biology, drug development) and dry-lab (bioinformatics, RNA sequencing) skills.
    • Active in editorial roles (Frontiers) and peer review (Scientific Reports, Oncogene, etc.).

Education 🎓

  • PhD in Molecular Genetics (2007–2012), Tarbiat Modares University (Thesis: Anticancer effects of dendrosomal nanocurcumin).
  • MSc in Molecular Genetics (2002–2005), Tarbiat Modares University.
  • BSc in Biology (1998–2002), Shahid Beheshti University.

Experience 💼

  • Professor (2021–present), University of Tabriz.
  • Research Fellow (2023), University of Tübingen, Germany (NGS data analysis).
  • Guest Scientist (2017, 2011), University of Salzburg, Austria (Flow cytometry, miRNA studies).
  • Lecturer (2005–2007), University of Tabriz.

Research Interests On Genetics 🔍

  • Cancer genetics: Biomarker discovery, apoptosis, and drug resistance.
  • Nanomedicine: Curcumin-based therapies (e.g., Curcuden35).
  • Bioinformatics: miRNA-target prediction tools (EBST), CRISPR/Cas9 applications.
  • Molecular diagnostics: Circulating nucleic acids for early cancer detection.

Awards & Honors 🏆

  • Best International Researcher Award, University of Tabriz (2024).
  • DFG Research Grant (2021) for RNA-seq training in Germany.
  • Young Investigator Award, INCTR Congress (2009).
  • Top ranks in national MSc/PhD entrance exams (2002, 2006).

Publications 📜

  • Title: Dendrosomal curcumin significantly suppresses cancer cell proliferation in vitro and in vivo
    Authors: E Babaei, M Sadeghizadeh, ZM Hassan, MAH Feizi, F Najafi, …
    Year: 2012
    Citations: 182

  • Title: Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells
    Authors: M Tahmasebi Mirgani, B Isacchi, M Sadeghizadeh, F Marra, AR Bilia, …
    Year: 2014
    Citations: 152

  • Title: MgrB Alterations Mediate Colistin Resistance in Klebsiella pneumoniae Isolates from Iran
    Authors: M Haeili, A Javani, J Moradi, Z Jafari, MM Feizabadi, E Babaei
    Year: 2017
    Citations: 113

  • Title: Curcumin-based nanoformulations: A promising adjuvant towards cancer treatment
    Authors: S Hafez Ghoran, A Calcaterra, M Abbasi, F Taktaz, K Nieselt, E Babaei
    Year: 2022
    Citations: 91

  • Title: The anti-proliferative and apoptotic effects of crocin on chemosensitive and chemoresistant cervical cancer cells
    Authors: H Mollaei, R Safaralizadeh, E Babaei, MR Abedini, R Hoshyar
    Year: 2017
    Citations: 73

  • Title: Dendrosomal nano-curcumin, the novel formulation to improve the anticancer properties of curcumin
    Authors: BM TAHMASEBI, MV ERFANI, E Babaei, F NAJAFI, M Zamani, M Shariati, …
    Year: 2015
    Citations: 62

  • Title: New dendrimer-based nanoparticles enhance curcumin solubility
    Authors: MC Falconieri, M Adamo, C Monasterolo, MC Bergonzi, M Coronnello, …
    Year: 2017
    Citations: 58

  • Title: Development of curcumin-loaded gemini surfactant nanoparticles: Synthesis, characterization and evaluation of anticancer activity against human breast cancer cell lines
    Authors: M Karimpour, MAH Feizi, M Mahdavi, B Krammer, T Verwanger, F Najafi, …
    Year: 2019
    Citations: 50

  • Title: Survivin as a potential target for cancer therapy
    Authors: E Soleimanpour, E Babaei
    Year: 2015
    Citations: 47

  • Title: Survivin-deltaEx3: a novel biomarker for diagnosis of papillary thyroid carcinoma
    Authors: S Vandghanooni, M Eskandani, V Montazeri, M Halimi, E Babaei, …
    Year: 2011
    Citations: 44

Conclusion 🌟

Dr. Babaei is a pioneer in molecular oncology, blending wet-lab expertise with bioinformatics to advance cancer therapeutics. His work on nanocurcumin, CRISPR-based diagnostics, and miRNA biomarkers highlights his interdisciplinary impact. With 95+ publications and leadership in international collaborations, he continues to drive innovation in genetics and personalized medicine.